Research Studies

The purpose of this study is to find out if different dose levels (amounts) of the study drug are safe. This study will also measure whether the study drug improves your vision.

Currently there is no approved treatment for Retinitis Pigmesntosa due to the P23H mutation. The study drug is designed to repair the problem that causes vision loss due to this mutation.

Main Procedures Involved: At each study visit, you will be asked about your health and several study assessments and tests will be performed.

Duration of Participation: Your participation will last for 12 months (1 year) from the time you will receive the study treatment. If you decide to take part in the study, you will have to visit the study site 9 to 13 times. It is possible that some of these visits will be planned on multiple consecutive days. You may need to stay overnight near the study site. You may bring someone with you. In exceptional cases, e.g. related to restrictions related to the COVID-19 pandemic, part of your visit may be performed by phone and/or the visit at your study site may be postponed to a later date.